The Board's Role in M&A

In this exclusive interview with Criticaleye, Oliver Tant, Non-executive Director at UK household name B&M Retail and former CFO of FTSE 100 stalwart Imperial Brands, highlights the vital role of the Board in providing guardrails around potential M&A transactions, drawing on his 40-plus year career.

Criticaleye provides Chairs, NEDs and SIDs with bespoke support designed to nurture high performance at Board level. With 93 percent of respondents in our Chair & NED Research recognising the need for Boards to have external reference points, Criticaleye facilitates a unique environment to benchmark with Board-level peers from various organisations, sectors and regions.
 
 
Click here to find out more about how we support Board leaders.





Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
CPO Research Results 2025

This research, conducted at our CPO Retreat, provides a fascinating insight into the challenges and priorities for Chief People Officers (CPOs) this year. Key findings from Criticaleye's CPO Research: Tec...

Click here to download this insight
2025 Customer Experience Repo...

This Customer Experience Report by Criticaleye Partner, ServiceNow,  reveals a growing ‘service gap’, where customer expectations are rising but service quality is falling. Agents face disjointed system...

Succeeding as a Regional CEO ...

In this episode, Yu-Wen Hsiao, Marketing and Communications Manager, APAC at Criticaleye, speaks with Terence Quek, CEO of the Singapore Institute of Directors. Drawing on over 20 years of experience in strategy, busine...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 329




Legal & General Investment Management Lightsource bp Google Amazon UK Hitachi Solutions Accenture LDC NATS Eightfold AI Royal London Group Workday Activision Blizzard Palo Alto Networks FTSE Women Leaders Review IBM Consulting AlixPartners Salesforce Concentrix E.ON UK Experian London Stock Exchange Group Rolls-Royce Drax Group plc GlaxoSmithKline plc